The EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (EEC project) is a UCL coordinated collaborative project involving 20 European partners, which has recently been awarded funding through the European Union's Framework Programme 7 (FP7).
Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases.
The Euro Ewing Consortium is a coalition of clinical study groups bringing together the most active clinicians and scientists in Europe dedicated to improving survival from ES. This initiative will support an integrated programme of investigator-driven, inclusive clinical trials that are rigorously designed, conducted, analysed and reported, and underpinned by complementary embedded translational research. Through collaborative working, the EEC will provide ES patients with greater access to clinical trials, allow efficient acquisition of knowledge and deliver clinically meaningful results within 5 years, thereby contributing to improved survival from ES.